Long-term consequences of osteoporosis therapy with denosumab
ABSTRACT Denosumab (DMAb) is a human monoclonal antibody used as an antiresorptive drug in the treatment of osteoporosis. Approval at a dosage of 60 mg every 6 months was based on the results of the randomized, placebo-controlled trial (FREEDOM). The design of this 3-year study included an extension...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Brazilian Society of Endocrinology and Metabolism
2022-12-01
|
| Series: | Archives of Endocrinology and Metabolism |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972022000500717&tlng=en |
| _version_ | 1811185980967747584 |
|---|---|
| author | Francisco Bandeira Lucian Batista de Oliveira John P. Bilezikian |
| author_facet | Francisco Bandeira Lucian Batista de Oliveira John P. Bilezikian |
| author_sort | Francisco Bandeira |
| collection | DOAJ |
| description | ABSTRACT Denosumab (DMAb) is a human monoclonal antibody used as an antiresorptive drug in the treatment of osteoporosis. Approval at a dosage of 60 mg every 6 months was based on the results of the randomized, placebo-controlled trial (FREEDOM). The design of this 3-year study included an extension for up to 10 years. Those who were randomized to DMAb continued on drug, while those who were randomized to placebo transitioned to DMAb. The 10-year experience with DMAb provides data on efficacy of drug in terms of reduced fractures and continued increases in bone mineral density (BMD). The 10-year experience with denosumab also provides information about rare complications associated with the use of DMAb, such as osteonecrosis of the jaw (ONJ), and atypical femoral fractures (AFF). This experience provided new insights into the reversibility of effects upon discontinuation without follow-on therapy with another agent. This review focuses upon prolonged treatment with DMAb, with regard to beneficial effects on fracture reduction and safety. Additionally, its use in patients with impaired renal function, compare its results with those of bisphosphonates (BPs), the occurrence/frequency of complications, in addition to the use of different tools, from imaging techniques to histological findings, to evaluate its effects on bone tissue. |
| first_indexed | 2024-04-11T13:38:40Z |
| format | Article |
| id | doaj.art-609b969c3ddf4b32bfbdbac357137b1c |
| institution | Directory Open Access Journal |
| issn | 2359-4292 |
| language | English |
| last_indexed | 2024-04-11T13:38:40Z |
| publishDate | 2022-12-01 |
| publisher | Brazilian Society of Endocrinology and Metabolism |
| record_format | Article |
| series | Archives of Endocrinology and Metabolism |
| spelling | doaj.art-609b969c3ddf4b32bfbdbac357137b1c2022-12-22T04:21:21ZengBrazilian Society of Endocrinology and MetabolismArchives of Endocrinology and Metabolism2359-42922022-12-0166571772310.20945/2359-3997000000560Long-term consequences of osteoporosis therapy with denosumabFrancisco Bandeirahttps://orcid.org/0000-0003-0290-0742Lucian Batista de Oliveirahttps://orcid.org/0000-0002-6930-0664John P. Bilezikianhttps://orcid.org/0000-0002-1570-2617ABSTRACT Denosumab (DMAb) is a human monoclonal antibody used as an antiresorptive drug in the treatment of osteoporosis. Approval at a dosage of 60 mg every 6 months was based on the results of the randomized, placebo-controlled trial (FREEDOM). The design of this 3-year study included an extension for up to 10 years. Those who were randomized to DMAb continued on drug, while those who were randomized to placebo transitioned to DMAb. The 10-year experience with DMAb provides data on efficacy of drug in terms of reduced fractures and continued increases in bone mineral density (BMD). The 10-year experience with denosumab also provides information about rare complications associated with the use of DMAb, such as osteonecrosis of the jaw (ONJ), and atypical femoral fractures (AFF). This experience provided new insights into the reversibility of effects upon discontinuation without follow-on therapy with another agent. This review focuses upon prolonged treatment with DMAb, with regard to beneficial effects on fracture reduction and safety. Additionally, its use in patients with impaired renal function, compare its results with those of bisphosphonates (BPs), the occurrence/frequency of complications, in addition to the use of different tools, from imaging techniques to histological findings, to evaluate its effects on bone tissue.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972022000500717&tlng=enDenosumabosteoporosisfracturesosteonecrosisbone remodeling |
| spellingShingle | Francisco Bandeira Lucian Batista de Oliveira John P. Bilezikian Long-term consequences of osteoporosis therapy with denosumab Archives of Endocrinology and Metabolism Denosumab osteoporosis fractures osteonecrosis bone remodeling |
| title | Long-term consequences of osteoporosis therapy with denosumab |
| title_full | Long-term consequences of osteoporosis therapy with denosumab |
| title_fullStr | Long-term consequences of osteoporosis therapy with denosumab |
| title_full_unstemmed | Long-term consequences of osteoporosis therapy with denosumab |
| title_short | Long-term consequences of osteoporosis therapy with denosumab |
| title_sort | long term consequences of osteoporosis therapy with denosumab |
| topic | Denosumab osteoporosis fractures osteonecrosis bone remodeling |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972022000500717&tlng=en |
| work_keys_str_mv | AT franciscobandeira longtermconsequencesofosteoporosistherapywithdenosumab AT lucianbatistadeoliveira longtermconsequencesofosteoporosistherapywithdenosumab AT johnpbilezikian longtermconsequencesofosteoporosistherapywithdenosumab |